Immuron Ltd. (IMRN), an Australian biopharmaceutical company, Monday reported its first-quarter global sales growth of Travelan, an over-the-counter immune supplement.
The company's global sales were up 34 percent to AUD$2.0 million compared to the previous year driven by increased awareness of the supplement through media marketing, increased new stores, and same store growth.
The sales for the first quarter in the U.S. rose 44 percent to AUD$0.4 million led by improved online sales and through paid social media marketing.
Travelan is a listed medicine on the Australian Register for Therapeutic Goods and is indicated to reduce the risk of minor gastro-intestinal disorders and is antimicrobial.
In the premarket trade today, shares were trading 3.38 percent or 0.07 cents higher at $2.14. On Friday, the stock had closed 3.27 percent or 0.07 cents lower at $2.07 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.